Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.50 |
| ▸ | HTR7 known ✓ | P34969 | 3/20 | 0.46 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.46 |
| ▸ | CACNA1G known ✓ | O43497 | 2/20 | 0.45 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.44 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7970723 | 0.99 | ACHE (0.51) | ACHEHTR7HTR1ACACNA1GALDH1A1 | |
| Hydrochloric Acid SCHEMBL5364551 | 0.91 | ACHE (0.51) | ACHEHTR7HTR1AALDH1A1TSHR | |
| SCHEMBL7984579 | 0.90 | ACHE (0.52) | ACHEHTR7HTR1AALDH1A1TSHR | |
| SCHEMBL7980861 | 0.87 | ACHE (0.53) | ACHEHTR7HTR1AALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL9050783 | 0.78 | MAPT (0.49) | ALDH1A1TSHRKDM4EKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5353029 | 0.77 | ACHE (0.53) | ACHEHTR7HTR1AALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL5353257 | 0.77 | KMT2A (0.50) | ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL222020 | 0.76 | ACHE (0.56) | ACHE | |
| SCHEMBL14577909 | 0.76 | ACHE (0.54) | ACHEHTR7HTR1AALDH1A1TSHR | |
| SCHEMBL14578069 | 0.76 | KMT2A (0.51) | ALDH1A1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236403-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATRICS CORPORATION (US) | 2003-12-25 | — | — | US | claimed |
| US-6306857-B1 | INHIBITION OF ABNORMALLY PHOSPHORYLATED | MOLECULAR GERIATRICS CORPORATION | 2001-10-23 | — | — | US | claimed |
| US-20010025105-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATARICS CORPORATION | 2001-09-27 | — | — | US | claimed |
| WO-1996015792-A1 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| US-7173132-B2 | Certain substituted 1-aryl-3-piperazine-1′-yl propanones | MOLECULAR GERIATRICS CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-20030236403-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATRICS CORPORATION (US) | 2003-12-25 | — | — | US | disclosed |
| US-6306857-B1 | INHIBITION OF ABNORMALLY PHOSPHORYLATED | MOLECULAR GERIATRICS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-20010025105-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATARICS CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6214994-B1 | TREATMENT OF NEOPLASTIC DISEASES, BACTERIAL OR FUNGAL INFECTIONS, AND PREVENTING OR DECREASING PRODUCTION OF PHOSPHORYLATED PAIRED HELICAL FILAMENT (PHF) EPITOPES ASSOCIATED WITH ALZHEIMER'S DISEASE | MOLECULAR GERIATRICS CORPORATION | 2001-04-10 | — | — | US | disclosed |
| US-6075026-A | Certain substituted 1-aryl-3-piperazin-1'-yl propanones | MOLECULAR GERIATRICS, CORP. (US) | 2000-06-13 | — | — | US | disclosed |
| US-5693804-A | USEFUL IN TREATING NEOPLASTIC DISEASES, BACTERIAL OR FUNGAL INFECTIONS AND ALZHEIMER'S DISEASE | MOLECULAR GERIATRICS CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0792269-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1997-09-03 | — | — | EP | disclosed |
| US-5658909-A | INHIBITION OF ABNORMALLY PHOSPHORYLATED PAIRED HELICAL FILAMENT EPITOPE FORMATION | MOLECULAR GERIATRICS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1996015792-A9 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | — | 1996-09-12 | — | — | WO | disclosed |
| WO-1996016052-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236403-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | PSEN1, PSEN2, PRNP | ACHE 3965/4885HTR7 2136/4885HTR1A 1027/4885 |
| US-20010025105-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | PSEN1, PSEN2, PRNP | ACHE 3965/4885HTR7 2136/4885HTR1A 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.